

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Enok TJOTTA

Conf.

Application No. NEW NATIONAL PHASE

Group

Filed April 6, 2005

Examiner

METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH
AND USE THEREOF**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)**Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 6, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☐ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel

Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/ia

Enclosures: ☒ Form PTO-1449(s)
☒ Documents
☒ Foreign Search Report
☐ Other: _____

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Attorney Docket No.:
3657-1025Application No.:
NEW NATIONAL PHASEApplicant:
Enok TJOTTAFiling Date:
April 6, 2005

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 01/00585	1/4/2001	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	The Prostate, Volume 32, 1997, Sven de Vos et al, "Effects of Retinoid X Receptor-Selective Ligands on Proliferation of Prostate Cancer Cells", pages 115-121, abstract
	Virology, Volume 23, No. 2, 1964, MacPherson I et al, "Agar Suspension Culture for the Selective Assay of Cells Transformed by Polyoma Virus", pages 291-294, see the whole document
	BIOSIS, accession no. PREV198172018181, Baird W M et al: "Comparison of the metabolism of benzo a pyrene and its activation to biologically active metabolites by low passage hamster and rat embryo cells", Carcinogenesis, vol. 2, No. 2, 1981 pages 81-88, abstract
	Journal of Clinical Hematology and Oncology, Volume 12, No. 3, 1982, Meischen S.J. et al, "Synthesis and anti tumor activity of N phosphonoacetyl-L-aspartato-1 2-diamino cyclo hexane platinum II", pages 67-76, see the whole document
	Gynecologic Oncology, Volume 17, No. 2, 1984, Weppelmann B et al, "The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix", pages 196-199, abstract
	Journal of Surgical Research, Volume 54, Issue 1, January 1993, Diane K. Stoller et al, "Reduction of Atherosclerosis with Nonsteroidal Anti-Inflammatory Drugs", pages 7-11, abstract
	Atherosclerosis, Volume 54, No. 2, 1985, Bailey JM et al, "Anti-inflammatory drugs in experimental atherosclerosis. Part 6. Combination therapy with steroid and non-steroid agents, pages 205-212, abstract

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience